publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
elsevi
veterinari
immunolog
aud
immunopatholog
veterinari
immunolog
immunopatholog
isotypespecif
antibodi
respons
bovin
herpesviru
sera
mucos
secret
calv
experiment
reinfect
reactiv
isotypespecif
antibodi
respons
bovin
herpesviru
bhv
measur
sera
nasal
ocular
genit
secret
calv
reinfect
bhv
week
later
treat
corticosteroid
reactiv
put
latent
viru
reinfect
reactiv
bhvlspecif
igm
antibodi
respons
detect
serum
iga
respons
transient
detect
reinfect
appear
rapidli
reactiv
calv
calv
show
increas
nasal
ocular
iga
titr
reinfect
reactiv
calv
also
iga
antibodi
genit
secret
salient
find
reinfect
reactiv
calv
show
serum
iga
respons
viru
shed
increas
serum
iggl
titr
suggest
serum
iga
respons
would
sensit
indic
detect
bhvl
reinfect
reactiv
correl
found
nasal
iga
titr
time
reinfect
corticosteroid
treatment
period
viru
shed
suggest
nasal
iga
play
major
role
protect
reinfect
bhvl
present
address
bovin
herpesviru
bhvl
caus
diseas
entiti
infecti
bovin
rhinotrach
infecti
pustular
vulvovagin
infecti
balanoposth
immun
induc
primari
bhvl
infect
rel
shortlast
cattl
may
reinfect
bhvl
cattl
infect
bhvl
lifelong
carrier
viru
latent
noninfecti
form
mainli
trigemin
ganglia
result
stress
simul
administr
corticosteroid
bhvi
reactiv
shed
environ
isotypespecif
antibodi
respons
reinfect
reactiv
bhvl
fragmentarili
studi
rodak
et
al
guy
potgiet
b
osorio
et
al
edward
et
al
extens
investig
respons
report
describ
kinet
sera
nasal
ocular
genit
secret
experiment
reinfect
corticosteroid
treat
calv
isotypespecif
antibodi
respons
primari
infect
recent
report
madic
et
al
previou
experi
madic
et
al
calv
randomli
divid
eight
group
four
calv
seven
group
intranas
infect
one
seven
bhvl
strain
one
group
serv
control
tabl
two
calv
inocul
iowa
strain
die
present
experi
remain
calv
inocul
intranas
spray
ml
nostril
contain
total
tcid
virul
iowa
strain
bhvl
kindli
provid
dr
jm
miller
nation
diseas
center
ame
iowa
week
primari
infect
titr
inoculum
verifi
viru
titrat
day
inocul
none
calv
develop
clinic
sign
characterist
bhv
except
primari
inocul
control
calv
six
week
reinfect
calv
treat
intramuscularli
mg
dexamethason
opticortenol
os
ciba
kg
bodi
weight
consecut
day
treatment
none
calv
develop
moder
sever
clinic
sign
blood
sampl
collect
postreinfect
day
prd
posttreat
day
ptd
ptd
mark
begin
corticosteroid
treatment
serum
obtain
whole
blood
cenuifug
store
test
nasal
ocular
genit
secret
collect
ptd
mucos
secret
collect
cotton
tip
medic
wire
equip
co
bath
ltd
potley
corsham
uk
suspend
ml
phosphat
buffer
salin
solut
ph
clarifi
centrifug
store
test
nasal
ocular
secret
genit
secret
absorb
cotton
tip
thu
dilut
log
factor
nasal
ocular
secret
genit
secret
blood
contamin
secret
check
sangurtest
boehring
gmbh
mannheim
germani
viru
isol
nasal
swab
collect
prd
nasal
ocular
swab
ptd
viru
isol
swab
describ
previous
kaashoek
et
al
appear
anttbodi
fourfold
higher
increas
titr
presampl
posit
number
day
viru
excret
perform
exactli
previous
report
madic
et
al
igm
antibodi
respons
detect
sera
secret
reinfect
calv
control
calv
infect
first
time
develop
igm
antibodi
respons
serum
nasal
ocular
secret
first
detect
prd
last
prd
corticosteroid
treatment
none
calv
develop
detect
igm
antibodi
bhvi
sera
secret
twentyon
calv
react
reinfect
detect
iga
respons
serum
tabl
mean
prd
first
detect
control
calv
develop
iga
serum
antibodi
mean
prd
first
detect
iga
antibodi
reinfect
calv
peak
around
prd
approxim
day
first
detect
mean
prd
last
detect
reinfect
calv
control
calv
nasal
secret
fourfold
higher
increas
iga
antibodi
titr
found
one
reinfect
calv
tabl
increas
occur
prd
mean
prd
first
detect
control
calv
iga
first
detect
nasal
secret
prd
iga
antibodi
peak
prd
gradual
decreas
thereaft
fig
three
calv
iga
antibodi
persist
day
corticosteroid
treatment
ptd
fourfold
higher
increas
ocular
secret
seen
reinfect
calv
tabl
prd
mean
prd
first
detect
control
calv
develop
iga
antibodi
ocular
secret
mean
prd
first
detect
mean
titr
ocular
secret
lower
nasal
secret
fig
calv
iga
persist
ocular
secret
ptd
individu
iga
antibodi
titr
secret
vari
consider
reinfect
calv
iga
antibodi
detect
low
level
genit
secret
day
tabl
iga
antibodi
detect
genit
secret
control
calv
corticosteroid
treatment
one
calf
develop
serum
iga
antibodi
tabl
averag
appear
blood
ptd
serum
iga
antibodi
remain
detect
period
vari
day
anim
still
present
ptd
mark
end
experi
two
calv
fourfold
higher
increas
iga
antibodi
note
nasal
secret
corticosteroid
treatment
ocular
secret
increas
found
three
calv
tabl
mean
ptd
increas
rang
nasal
secret
rang
ocular
secret
peak
mucos
iga
titr
around
ptd
reach
valu
compar
reinfect
fig
individu
mucos
iga
antibodi
titr
fluctuat
consider
persist
end
experi
nine
calv
iga
antibodi
detect
genit
secret
five
also
genit
iga
antibodi
reinfect
tabl
ocular
iga
calv
reinfect
lead
signific
increas
igg
antibodi
titr
serum
remain
five
calv
fourfold
higher
increas
detect
prd
control
calv
iggl
antibodi
first
detect
prd
cours
mean
serum
igg
titr
per
group
given
fig
nine
calv
two
control
minim
iggl
antibodi
titr
mean
log
titr
nasal
secret
reinfect
calv
ocular
secret
mean
log
titr
short
period
none
secret
erythrocyt
detect
genit
secret
neg
tabl
corticosteroid
treatment
calv
show
signific
increas
iggl
antibodi
titr
serum
usual
ptd
igg
antibodi
titr
remain
stabl
cours
mean
serum
iggl
titr
per
group
given
fig
nasal
secret
calv
low
level
iggl
antibodi
mean
log
titr
detect
ocular
secret
calv
mean
log
titr
period
vari
day
approxim
onethird
nasal
secret
erythrocyt
pull
demonstr
erythrocyt
detect
ocular
secret
two
calv
igg
antibodi
genit
secret
free
erythrocyt
tabl
reinfect
induc
fourfold
higher
rise
serum
antibodi
titr
calv
prd
control
calv
induc
serum
respons
prd
develop
mean
serum
titr
shown
fig
three
calv
show
low
level
antibodi
mean
log
titr
nasal
secret
reinfect
none
antibodi
ocular
genit
secret
reinfect
tabl
corticosteroid
treatment
serum
antibodi
titr
significantli
increas
calv
ptd
develop
mean
serum
titr
shown
fig
thirteen
calv
detect
level
antibodi
mean
log
titr
nasal
secret
calv
genit
secret
none
antibodi
ocular
secret
tabl
number
day
viru
excret
per
individu
calf
reinfect
corticosteroid
treatment
given
tabl
reinfect
bhvl
shed
prd
mean
prd
first
detect
corticosteroid
treatment
viru
excret
usual
detect
ptd
mean
ptd
first
detect
correl
nasal
ocular
iga
antibodi
titr
time
reinfect
corticosteroid
treatment
respect
viru
excret
period
individu
calf
eg
calv
nasal
iga
reinfect
shed
bhvl
shorter
time
calv
high
nasal
iga
titr
reinfect
data
shown
calv
viru
excret
reinfect
andor
corticosteroid
treatment
detect
yet
develop
antibodi
respons
bhvl
mainli
iga
isotyp
primari
infect
induc
solid
immun
intranas
reinocul
high
dose
virul
bhvl
strain
prevent
viru
shed
calv
remain
calv
reinfect
led
day
minim
viru
excret
wherea
primari
infect
control
typic
viru
excret
pattern
kaashoek
et
al
spite
minim
viru
replic
calv
respond
antibodi
format
reinfect
corticosteroid
treatment
viru
replic
longer
higher
titr
nasal
ocular
mucosa
result
pronounc
antibodi
respons
bhvlspecif
igm
antibodi
respons
detect
reinfect
reactiv
cattl
either
sera
mucos
secret
intranas
reexposur
bhv
guy
potgiet
observ
slight
increas
igm
antibodi
titr
wherea
intraamniot
inocul
rapid
increas
detect
abort
addit
detect
secondari
igm
antibodi
respons
reactiv
guy
potgiet
discrep
may
explain
differ
igm
detect
method
differ
experiment
design
includ
breed
cattl
strain
dose
viru
rout
durat
corticosteroid
treatment
osorio
et
al
could
detect
igm
antibodi
respons
bhvl
reactiv
either
reactiv
herp
simplex
viru
igm
antibodi
respons
seldom
observ
associ
sever
enceph
kalimo
et
al
van
loon
et
al
howev
reactiv
herp
zoster
viru
often
lead
igm
respons
tedder
et
al
reinfect
calv
bovin
respiratori
syncyti
viru
brsv
igm
detect
sera
detect
nasal
ocular
secret
kimman
et
al
howev
pathogenesi
brsv
infect
differ
bhvl
infect
latter
give
rise
clinic
sign
upper
respiratori
tract
wherea
brsv
infect
mainli
affect
lower
respiratori
tract
one
salient
find
studi
calv
temporari
iga
serum
respons
demonstr
reinfect
reactiv
serum
iga
respons
reinfect
reactiv
calv
much
earlier
detect
primari
infect
calv
indic
memori
respons
rodak
et
al
edward
et
al
could
detect
serum
iga
respons
bhv
reinfect
calv
eleven
calv
viru
excret
could
detect
reinfect
andor
reactiv
even
show
clear
system
iga
antibodi
respons
explan
unexpect
tind
may
latent
infect
calv
given
corticosteroid
noninfecti
physic
rather
infecti
bhvl
particl
may
produc
pastoret
et
al
physic
particl
stimul
antibodi
respons
howev
discrep
viru
excret
antibodi
respons
may
due
failur
detect
infecti
viru
particl
excret
via
nasal
ocular
secret
one
nasal
ocular
swab
taken
per
h
howev
may
serum
iga
respons
seem
much
sensit
indic
reinfect
reactiv
bhvl
detect
nasal
ocular
viru
shed
case
brsv
infect
secondari
serum
iga
respons
transient
persist
month
kimman
et
al
vigor
iga
respons
serum
also
secondari
type
iga
antibodi
respons
observ
nasal
ocular
secret
reinfect
reactiv
calv
mucos
iga
respons
reinfect
rapid
stronger
primari
infect
calv
fig
indic
exist
mucos
memori
thu
confirm
earlier
report
brsv
bovin
corona
viru
infect
kimman
et
al
heckert
et
al
primari
infect
madic
et
al
iga
antibodi
detect
genit
secret
wherea
probabl
result
prime
reinfect
reactiv
genit
iga
antibodi
found
calv
increas
nasal
iga
antibodi
follow
onset
viru
shed
period
sever
day
suggest
exist
nasal
iga
antibodi
neutralis
bhvi
madic
et
al
play
major
role
curtail
amount
viru
shed
reinfect
reactiv
substanti
find
correl
exist
nasal
iga
titr
reinfect
onset
corticosteroid
treatment
one
hand
viru
shed
period
wherea
calv
viru
nasal
secret
five
increas
serum
iggl
titr
serum
titr
reinfect
guy
potgiet
also
found
antibodi
increas
reinfect
frequent
iggl
isotyp
corticosteroid
treatment
virusposit
nasal
secret
detect
reinfect
calv
signific
increas
serum
iggl
antibodi
titr
calv
respect
correspond
viru
shed
antibodi
titr
increas
tabl
inabl
calv
elicit
booster
iggl
serum
antibodi
respons
may
partial
due
high
antibodi
titr
alreadi
exist
reinfect
corticosteroid
treatment
case
calv
react
system
iga
respons
reinfect
corticosteroid
treatment
system
iggl
respons
support
system
iga
respons
sensit
indic
bhvl
reinfect
reactiv
particularli
reactiv
also
reinfect
iggl
antibodi
seen
nasal
ocular
secret
antibodi
detect
nasal
secret
fewer
calv
iggl
antibodi
igg
contain
secret
free
erythrocyt
exclud
leakag
blood
caus
igg
presenc
whether
transud
select
transport
serum
mucos
product
respons
mucos
igg
conclus
determin
iggl
antibodi
ratio
serum
usual
correspond
nasal
secret
data
shown
indic
select
transport
iggl
rather
transud
serum
isotyp
never
detect
ocular
secret
primari
infect
madic
et
al
reinfect
reactiv
suggest
isotyp
may
rare
pass
conjunctiv
mucosa
find
also
favour
select
transport
iggl
ocular
mucou
membran
iggl
antibodi
bhv
detect
genit
secret
calv
corticosteroid
treatment
clear
differ
period
viru
shed
corticosteroid
treatment
group
calv
primari
infect
differ
bhvl
strain
eg
calv
given
cooper
strain
far
longest
viru
shed
period
nose
eye
differ
viru
shed
howev
result
mark
differ
isotypespecif
antibodi
respons
group
calv
knowledg
extens
studi
perform
isotypespecif
antibodi
respons
bhvl
reinfect
reactiv
may
conclud
igm
isotyp
absent
secondari
tertiari
antibodi
respons
bhvi
serum
iga
respons
sensit
indic
bhvl
reinfect
reactiv
viru
shed
increas
iggl
serum
titr
addit
nasal
iga
antibodi
appear
involv
virolog
protect
reinfect
reactiv
